Abbott Laboratories (NYSE:ABT) reported on Wednesday a notable increase in its first quarter sales for 2024, which rose by 2.2% to reach $9.9 billion, surpassing analysts’ expectations. However, the company experienced a decline in net earnings, which fell by 7.0% to $1.2 billion, and diluted earnings per share (EPS) decreased by 6.7% to $0.70.

Despite the downturn in profitability, the healthcare giant has adjusted its financial outlook upwards for the year. Abbott now forecasts a full-year diluted EPS on a GAAP basis to be between $3.25 and $3.40. Additionally, the company’s full-year 2024 organic sales growth guidance is projected to range from 8.5% to 10.0%.

Chairman and CEO Robert B. Ford expressed optimism about the company’s performance, stating, “Our first-quarter results reflect a strong start to the year, and we are raising our full-year sales and EPS guidance […] This was the fifth consecutive quarter that we delivered double-digit organic sales growth in our underlying base business.” This statement highlights the company’s confidence in its operational strength and its ability to sustain growth amidst challenging market conditions.

Join the discussion: Connect with other investors on your favorite stocks or explore the top-talked-about stocks on our Breakout Boards.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.